Evidence map›Paper›PMID 42712125›Full record

ArticleDiabetes, obesity & metabolism2026

GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Trial: Rationale, Design and Baseline Characteristics.

J M Samuels, C R Williams, M B Patel, W H Self, L M Funk, C Roumie, M D Spann, C J Northup, F Ye, R Irlmeier and 3 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT06162715. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06162715 phase2 / phase3active not recruiting

GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

Ran2024Enrolled30Registered outcomes16Posted comparisons0ConditionsBMI Greater Than 30, Obesity, Severe ObesityArmsStandard of Care post-gastric bypass, Tirzepatide
Open the trial in the graph
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

J M SamuelsDepartment of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID https://orcid.org/0000-0001-5427-3117
C R WilliamsVanderbilt Medical Student Research Training Program, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID https://orcid.org/0009-0008-1267-8464
M B PatelDepartment of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
W H SelfDepartment of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
L M FunkDepartment of Surgery, University of Wisconsin-Madison, Madison, Wisconsin, USA.
C RoumieDepartment of Surgery, William S. Middleton Veterans Health Administration Hospital, Madison, Wisconsin, USA.
M D SpannDepartment of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
C J NorthupDepartment of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
F YeDepartment of Public Health Sciences, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
R IrlmeierDepartment of Public Health Sciences, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
I SohnDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Y ZhuDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
K NiswenderTennessee Valley VA Health Care System, Nashville, Tennessee, USA.

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALVIN C POWERS · 2012 to 2026
$29.3M
Use of Adjuvant Anti-Obesity Medication to Enhance Surgical Weight LossK23DK143312 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jason Samuels · 2025 to 2026
$355k
National Center for Advancing Translational Sciences/National Institutes of Health UL1 TR000445National Center for Advancing Translational Sciences/National Institutes of Health UL1 TR002243NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR002243NIDDK NIH HHS K23 DK143312NIDDK NIH HHS K23DK143312NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK058404Vanderbilt Diabetes and Research Training Center DK20593Vanderbilt Digestive Disease Research Center P30 DK058404
6 · The paper itself

Abstract

aimsNo studies have investigated the synergistic effectiveness of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs) in patients with persistent obesity following bariatric surgery. The GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Trial aims to investigate the effectiveness of tirzepatide (TRZ) versus standard of care (SOC) after Roux-en-Y gastric bypass (RYGB) in patients with persistent obesity (body mass index [BMI] ≥ 30 kg/m MATERIALS AND

methodsThis randomized, open-label proof-of-concept trial compares 24 weeks of TRZ with SOC versus SOC alone after RYGB. The primary outcome is total percent weight change from baseline to 24 weeks after trial initiation. Patients aged 25-65 with BMI ≥ 30 kg/m

resultsThe study enroled 33 patients, with 5 withdrawals prior to completing a baseline visit, resulting in a final sample of 28 patients. The final cohort is 82% female, 75% white, median age 42.0 years, pre-surgery BMI of 48.3 kg/m

conclusionsGRABS is the first randomized trial to investigate GLP1RA effectiveness in patients with persistent obesity following RYGB, with the potential to inform synergistic adjuvant strategies to enhance surgical weight loss.

trial registrationClinicalTrials.gov identifier: NCT06162715.

Indexed as

Bariatric SurgeryGastric BypassGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsObesity, MorbidAdultAgedBody Mass IndexClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicFemaleHumansMaleMiddle AgedObesityPostoperative CareGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsTirzepatidebariatric surgeryGLP‐1 receptor agonistGRABS trialmultimodal obesity treatmentobesity management medicationweight recurrence

Identifiers

PMID42712125
PMCPMC13646343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.